3 Mid-Cap Growth Stocks With Monstrous Long-Term Upside
Investing in mid-cap stocks with modest valuations can set investors up for significant returns in the long run. Three mid-cap stocks that may have a lot of room to rise higher in the future are Archer Aviation, CRISPR Therapeutics, and e.l.f. Beauty.
Intelligence analysis by Llama
Investing in mid-cap stocks with modest valuations can set investors up for significant returns in the long run. Three mid-cap stocks that may have a lot of room to rise higher in the future are Archer Aviation, CRISPR Therapeutics, and e.l.f. Beauty.
Imagine you're in a big city with lots of traffic. There's a new way to travel that's like a taxi, but it flies! This company, Archer Aviation, is working on making that happen. They're also making special planes for the military and for people to use for work. It's a big risk, but it could be really cool and helpful.
Analysis
A $60B Vote of Confidence
Archer Aviation is a leading player in the electric vertical take-off and landing (eVTOL) industry, potentially revolutionizing how people travel and commute. It hasn't obtained certification for its Midnight aircraft yet, and it may still incur sizable losses for multiple years. For investors, that means the risk of frequent stock offerings and heavy dilution can't be overlooked. But there is considerable potential in the space as air taxis could alleviate traffic in major cities.
Why Cursor?
CRISPR Therapeutics is a small but promising player in the gene therapy market. It has developed Casgevy along with its partner, Vertex Pharmaceuticals. Casgevy is approved to treat a couple of rare blood disorders: sickle cell disease and beta thalassemia. It's such a game changer for patients that experts believe it's still a cost-efficient option at a price of $2.2 million for a one-time treatment.
The Road Ahead
e.l.f. Beauty is in the best financial shape of the stocks listed here. Tariffs and trade wars have weighed on its business, but overall, the company has been doing well. In its most recent fiscal year, which ended on March 31, net sales of $1.6 billion rose by 25%, and its adjusted net income totaled $185.9 million. While e.l.f. has been a top growth stock to own in the past, concerns around tariffs have made investors more bearish on it of late.
Key points
- Archer Aviation is a leading player in the eVTOL industry.
- CRISPR Therapeutics has developed Casgevy, a treatment for rare blood disorders.
- e.l.f. Beauty is in the best financial shape of the stocks listed here.
- Archer Aviation's stock has struggled this year, falling 38% thus far.
- CRISPR Therapeutics' stock is down 12% year to date.
If Archer Aviation's Midnight aircraft gets certified, it could be a game-changer for air travel. CRISPR Therapeutics' Casgevy treatment could also be a huge success, and e.l.f. Beauty's growth prospects look promising.
Archer Aviation's financial struggles could continue, and CRISPR Therapeutics' slow progress may be a concern for investors. e.l.f. Beauty's business could be affected by tariffs and trade wars.
